JMP Securities Maintains Market Outperform on MorphoSys, Lowers Price Target to $15
JMP Securities analyst Jason Butler maintains MorphoSys (NASDAQ:MOR) with a Market Outperform and lowers the price target from $32 to $15.
Roche’s Alzheimer’s Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
Earlier today, MorphoSys AG (NASDAQ:MOR) and its partner Roche Holdings AG (OTC:RHHBY) reported disappointing results from gantenerumab studies in mild cognitive impairment (MCI) due…
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday’s Mid-Day Session
Gainers
Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.
Roche’s Another Alzheimer’s Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months
MorphoSys AG’s (NASDAQ:MOR) partner Roche Holdings AG (OTC:RHHBY) announced results from the GRADUATE I and II studies evaluating gantenerumab in mild cognitive impairment…
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers
PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.
21 Stocks Moving in Wednesday’s Pre-Market Session: Revlon, La-Z-Boy, Houston American, Ovintiv And More
Gainers
Codex DNA, Inc. (NASDAQ: DNAY) rose 64.5% to $3.52 in pre-market trading after declining 10% on Tuesday.
55 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Sidus Space, Inc. (NASDAQ: SIDU) shares surged 92.4% to $2.77 after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity services contract with a potential value of $3.5 billion.